In injectable atropine sulfate formulations intended for equine and companion-animal emergency protocols, the API is dissolved in Water for Injection at a target concentration of 0.5–1.0 mg/mL, calculated on the anhydrous atropine sulfate basis. The formulation pH is adjusted with 0.1 N sulfuric acid or sodium hydroxide to 3.5–5.5, because atropine sulfate undergoes hydrolytic degradation to tropine and tropic acid at an accelerated rate above pH 6.0 and under prolonged thermal input. Vials are filled under a nitrogen overlay with residual headspace oxygen held below 5% to limit oxidative degradation of the tropane ester linkage. Terminal steam sterilization at 121°C for 15 min is acceptable only for formulations buffered in the pH 4.0–5.0 window; outside that window, aseptic filtration through a 0.22 µm polyvinylidene difluoride membrane is selected to avoid heat-induced potency loss. Multi-dose presentations incorporate benzyl alcohol at 1.5% v/v or chlorobutanol at 0.5% w/v as antimicrobial preservative, with preservative efficacy evaluated according to USP <51> across the labeled in-use interval. The finished injection is tested according to USP <1> Injections, USP <71> Sterility Tests, USP <85> Bacterial Endotoxins, and USP <788> Particulate Matter in Injections, with particulate counts controlled for particles ≥ 10 µm and ≥ 25 µm per container. Typical clinical dosing for preanesthetic parasympatholysis in dogs and horses falls in the range of 0.02–0.04 mg/kg intravenous, intramuscular, or subcutaneous; organophosphate poisoning protocols may require 0.2–0.5 mg/kg, with one-quarter of the total dose given intravenously and the remaining portion administered intramuscularly or subcutaneously, repeated according to clinical response. Finished product types emerging from this manufacturing route include single-dose 1 mL glass vials, multi-dose 10 mL and 50 mL Type I glass vials, and preservative-free syringes prepared by aseptic filling. On production-scale lines, potency drift has been observed when the pH is not re-checked after nitrogen sparging, because carbon dioxide displacement can raise the solution pH and reduce atropine sulfate recovery in subsequent HPLC quantification; batch records therefore include a post-sparge pH verification step before sterile filtration. Atropine sulfate monohydrate, the common solid-state form, contains approximately 0.83 mg of atropine base per 1.0 mg of the hydrated sulfate salt, which must be accounted for when calculating label claim on an atropine base equivalent basis. The API is not combined with strongly alkaline buffer systems or primary amine-containing stabilizers in injectable matrices, since both conditions accelerate ester hydrolysis during shelf life.

How Does Ophthalmic Atropine Sulfate Solution Balance Mydriatic Efficacy Against Corneal Toxicity in Repeated Equine Instillation?

Compounding of ophthalmic atropine sulfate solutions for equine recurrent uveitis and diagnostic mydriasis uses a 1% w/v concentration, equivalent to 10 mg/mL atropine sulfate, which is at the high end of the therapeutic mydriatic range for horses and requires tight controls on tonicity and antimicrobial properties. The vehicle is prepared by dissolving the API in sterile purified water at 20–25°C, then adding sodium chloride and boric acid to achieve osmolality between 280–320 mOsm/kg; this range is maintained because hypotonic ophthalmic solutions increase corneal epithelial permeability, while hypertonic solutions produce reflex lacrimation and reduce contact time on the corneal surface. The pH is adjusted to 3.5–6.0 with hydrochloric acid or sodium hydroxide, and the solution is protected from prolonged light exposure because atropine sulfate undergoes photodegradation in aqueous media under ultraviolet stress. For multi-dose dropper bottles, benzalkonium chloride is included at 0.01% w/v as preservative and is tested per USP <51> Antimicrobial Effectiveness Testing; preservative-free unit-dose containers are filled aseptically and are intended for single-use administration or for use in eyes with compromised corneal epithelium. The addition ratio in this scenario is strictly defined by the 1% w/v target, but overages of 2–5% are not typically applied because atropine sulfate stability in acidic ophthalmic solution is sufficient to maintain label claim through the labeled in-use period when light and headspace oxygen are controlled. Downstream production uses a compounding flow sequence: API dissolution in 80% of the final purified water volume, addition of tonicity agents and preservative, pH adjustment, volume completion, then sterile filtration through a 0.22 µm polyethersulfone membrane into low-density polyethylene ophthalmic dropper bottles. The finished product is tested under USP <771> Ophthalmic Products for pH, osmolality, and preservative content, and labelled for protected storage at 15–25°C in amber or opaque containers to minimize photolytic degradation. Terminal product types include 5 mL and 15 mL multi-dose ophthalmic droppers, 0.3 mL preservative-free unit-dose vials, and ophthalmologist-dispensed amber glass bottles sealed with polypropylene dropper caps. Field experience with equine patients indicates that repeated instillation schedules, often every 6–12 h during active uveitis, require preservative efficacy to be maintained for the entire 28-day in-use period; failure to meet this requirement has been associated with Pseudomonas contamination in ophthalmic containers when the closure is not resealed promptly after dosing. In compounding pharmacies, batch-to-batch tonicity variance is the most common deviation, corrected by rejecting lots that fall outside the 280–320 mOsm/kg specification rather than by adjusting after filtration.

For low-dose combination diphenoxylate/atropine sulfate tablets intended for canine gastrointestinal hypermotility, the manufacturing route is determined by the 100:1 ratio between diphenoxylate hydrochloride and atropine sulfate. Each compressed tablet contains 2.5 mg diphenoxylate hydrochloride and 0.025 mg atropine sulfate, which places atropine sulfate in the ultra-low-dose solid oral classification and makes blend uniformity the critical process parameter. The addition ratio is fixed at 0.025 mg per tablet, but the pharmaceutical overage for atropine sulfate is typically held at 0–2% because the API is stable in dry solid matrices and does not require significant compensation for loss during compression. The downstream process begins with a 1:10 geometric trituration of atropine sulfate with 200 mesh spray-dried lactose monohydrate, passed through a 60-mesh stainless steel sieve to break agglomerates. This trituration is then added to a low-shear bin blender containing diphenoxylate hydrochloride, microcrystalline cellulose, croscarmellose sodium, and preblended magnesium stearate; blending is carried out at 15 rpm for 20 min, with blend uniformity samples taken from at least 10 locations and analyzed by high-performance liquid chromatography with UV detection at 214 nm. Content uniformity failures have been observed on production lines when the atropine sulfate particle size distribution D90 exceeds 100 µm, because the active segregates from the finer carrier during tablet press hopper vibration; jet-milling the API to a D90 below 75 µm reduces this segregation risk. Tablets are compressed on a rotary tablet press to a target weight of 80 mg, hardness of 40–70 N, and friability below 1.0%. The finished tablets are tested for potency, content uniformity, disintegration, and dissolution according to the following matrix:

Terminal product types from this route include round, scored tablets of 2.5 mg/0.025 mg strength packaged in 100-count high-density polyethylene bottles with induction-sealed closures and unit-dose aluminum foil blisters. The combination is not formulated as an extended-release matrix because the antimuscarinic component has a narrow therapeutic index and requires immediate release for predictable dose titration in canine patients. Published data for use of this low-dose combination in feline patients is more limited, and the formulation is generally not scaled to feline dosing without recompounding to a lower tablet weight or capsule form. The manufacturing process does not use wet granulation for the atropine sulfate fraction, because the API is highly potent and wet massing introduces unnecessary loss of analytical recovery during drying; direct compression after trituration is the preferred route for this strength. In-process controls include loss-on-drying of the dried granules prior to compression, with moisture content held below 2.0% to avoid atropine sulfate hydrolysis during storage.

Lactose-Based Atropine Sulfate Triturations Supplied as Compounding Premixes for Capsule and Suspension Workflows

Compounding of atropine sulfate triturations in veterinary pharmacies uses a two-stage geometric dilution of the API with 200 mesh lactose monohydrate to produce 1:10 and 1:100 w/w premixes for extemporaneous prescription preparation. The 1:10 premix contains 10% atropine sulfate by weight, while the 1:100 premix contains 1% atropine sulfate; these dilution ratios reduce weighing error in low-dose oral capsule and suspension compounding and create a safer handling matrix for a potent antimuscarinic drug. The API is first milled through a 60-mesh stainless steel sieve, then diluted in a porcelain mortar using the geometric method, or in a planetary mixer equipped with a nylon-bladed head for batch sizes above 500 g. Blend uniformity is verified by high-performance liquid chromatography with an acceptance range of 90.0–110.0% of theoretical concentration and relative standard deviation below 5.0% across at least 10 sampling points. The diluent is selected for its chemical inertness with the tropane ester group; lactose monohydrate does not promote atropine sulfate hydrolysis under normal storage conditions at 20–25°C and relative humidity below 60%. The downstream process is nonsterile and is governed by USP <795> Nonsterile Compounding, with additional reference to USP <1176> for bulk powder and granulation sampling where applicable. Terminal product types generated from these triturations include oral capsules with strengths typically ranging from 0.01 mg to 0.4 mg atropine sulfate, oral suspensions prepared by levigating the trituration with a suspending vehicle, and oral pastes for veterinary administration. The premix format is not approved for medicated feed in food-producing species under major regulatory frameworks; atropine sulfate is not incorporated into production animal feed or drinking water premixes because of residual pharmacologic effects, narrow therapeutic index, and lack of residue depletion data for edible tissues. Therefore, the term premix in this scenario refers exclusively to a compounding intermediate for individualized veterinary prescriptions, not a feed additive premix. Pharmacists and veterinary compounders must label these triturations with beyond-use dates assigned according to USP <795>, typically not exceeding 180 days for dry powder mixtures stored in tightly closed, light-resistant containers. Batch-to-batch variance in these triturations is most often associated with incomplete cleaning of mortar surfaces between geometric dilution steps; validated cleaning procedures and dedicated equipment sets for atropine sulfate are recommended to avoid cross-contamination and carryover of a pharmacologically potent antimuscarinic substance into subsequent compounded preparations.

In multi-dose injectable presentations for cattle and swine, the formulation team must reconcile preservative efficacy against the hydrolytic degradation of atropine sulfate during in-use storage. The solution is prepared at a target concentration of 0.5–1.0 mg/mL atropine sulfate in Water for Injection, with sodium chloride added for isotonicity and pH adjusted to 4.0–5.0 using 0.1 N sulfuric acid. This pH window supports the antimicrobial effect of benzyl alcohol at 1.5% v/v while limiting the rate of hydrolysis of the tropane ester to below the threshold at which shelf-life potency fall outside the 90.0–110.0% label claim range. Steam sterilization at 121°C for 15 min is applied only after pH verification, because atropine sulfate hydrolyzes rapidly above pH 5.5 during autoclave dwell and cool-down phases; where pH cannot be held below 5.5, the process is shifted to aseptic filtration through a 0.22 µm membrane. The product is filled into Type I borosilicate glass vials under nitrogen, and headspace oxygen is controlled to below 5% to prevent oxidative degradation of the phenylacetate portion of the molecule. Compliance for food-producing species requires conformance to FDA 21 CFR 210 and 211 current good manufacturing practice for finished pharmaceuticals, as well as USP <1>, <71>, <85>, and <788> for the parenteral dosage form. Preservative efficacy is validated per USP <51> across the labeled in-use interval, which is commonly 28 days for multi-dose vials in field conditions; repeat needle puncture into 100 mL and 250 mL vials requires that the closure maintain seal integrity after multiple insertions, and coring of elastomeric stoppers has been identified as a failure mode when 18-gauge or larger vented needles are used repeatedly. Terminal product types include 100 mL and 250 mL multi-dose vials for intravenous, intramuscular, or subcutaneous administration in cattle, swine, and sheep. Withdrawal periods for meat and milk are product-label specific and not harmonized across jurisdictions; published residue depletion data for atropine sulfate in food-producing animals are limited, so formulators should not assign a default withdrawal time without submission of tissue and milk residue data to the relevant regulatory authority. Extralabel use in food-producing animals in the United States is subject to the restrictions of FDA 21 CFR 530, and use in animals intended for human consumption must be justified under veterinary oversight with a documented extended withdrawal period if no approved label exists for the species and indication.